Vas Narasimhan, Novartis CEO (Jason Alden/Bloomberg via Getty Images)

August 15, 2022 07:01 AM EDT

Sometimes you win. Sometimes you lose. And sometimes it's just another PhIII canakinumab fail

At this stage of the game, Novartis CEO Vas Narasimhan may be wishing he’d never even heard of canakinumab.

After steering the drug straight to …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE LOG IN

ENDPOINTS CAREERS

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

view job offer post your job now

TRENDING NOW

Trump asks 'very tough hombre' Dr. Oz to lead MFN talks

US warns drugmakers against misrepresenting cost of imported products

Endpoints 100 biotech survey: Welcome to the summer of biotech’s discontent

Meet the ‘first sale’ rule: A customs loophole pharma companies could use to ease tariff impact

About 5% of CBER and CDER left after FDA staff cuts, analysis finds

sponsored

Does your supply chain hold up under pressure for high-risk temperature-critical shipments?